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Mitochondrial Unfolded Protein Response
During Chronic Pressure Overload
Ioannis Smyrnias, PHD,a,* Stephen P. Gray, PHD,a,* Darlington O. Okonko, PHD,a Greta Sawyer, PHD,a
Anna Zoccarato, PHD,a Norman Catibog, RDCS,a Begoña López, PHD,b Arantxa González, PHD,b Susana Ravassa, PHD,b
Javier Díez, MD, PHD,b,c Ajay M. Shah, MDaABSTRACTISS
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MaBACKGROUND The mitochondrial unfolded protein response (UPRmt) is activated when misfolded proteins accumulate
within mitochondria and leads to increased expression of mitochondrial chaperones and proteases to maintain protein
quality and mitochondrial function. Cardiac mitochondria are essential for contractile function and regulation of cell
viability, while mitochondrial dysfunction characterizes heart failure. The role of the UPRmt in the heart is unclear.
OBJECTIVES The purpose of this study was to: 1) identify conditions that activate the UPRmt in the heart; and 2) study
the relationship among the UPRmt, mitochondrial function, and cardiac contractile function.
METHODS Cultured cardiac myocytes were subjected to different stresses in vitro. Mice were subjected to chronic
pressure overload. Tissues and blood biomarkers were studied in patients with aortic stenosis.
RESULTS Diverse neurohumoral or mitochondrial stresses transiently induced the UPRmt in cultured cardiomyocytes.
The UPRmt was also induced in the hearts of mice subjected to chronic hemodynamic overload. Boosting the UPRmt with
nicotinamide riboside (which augments NADþ pools) in cardiomyocytes in vitro or hearts in vivo significantly mitigated
the reductions in mitochondrial oxygen consumption induced by these stresses. In mice subjected to pressure overload,
nicotinamide riboside reduced cardiomyocyte death and contractile dysfunction. Myocardial tissue from patients with
aortic stenosis also showed evidence of UPRmt activation, which correlated with reduced tissue cardiomyocyte death and
fibrosis and lower plasma levels of biomarkers of cardiac damage (high-sensitivity troponin T) and dysfunction (N-ter-
minal pro–B-type natriuretic peptide).
CONCLUSIONS These results identify the induction of the UPRmt in the mammalian (including human) heart exposed
to pathological stresses. Enhancement of the UPRmt ameliorates mitochondrial and contractile dysfunction,
suggesting that it may serve an important protective role in the stressed heart. (J Am Coll Cardiol 2019;73:1795–806)
© 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).T he mammalian heart has the highest oxygenconsumption rate of any organ, which maytransiently increase several-fold during
physiological exercise to support the increased
cardiac workload. Chronic increases in cardiac work-
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ABBR EV I A T I ON S
AND ACRONYMS
Atf5 = cyclic AMP-dependent
transcription factor ATF-5
CHOP = CCAT-enhancer-
binding protein homologous
protein
ClpP = ATP-dependent Clp
protease proteolytic subunit
G-TPP = gamitrinib-
triphenylphosphonium
Hsp10 = heat shock 10kDa
protein 1
Hsp60 = heat shock 60kDa
protein 1
LonP1 = lon protease homolog,
mitochondrial
mtDNAj = mitochondrial
pre-sequence translocase-
associated motor complex
protein (PAM16)
NR = nicotinamide riboside
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1796Mitochondria are crucial for cardiac func-
tion through oxidative ATP generation to
support muscle contraction and relaxation,
the metabolism of nucleotides, amino acids
and lipids, intracellular calcium buffering,
and the regulation of cardiomyocyte sur-
vival. Mitochondrial dysfunction is a central
feature of heart failure by contributing to
energetic dysfunction, oxidative stress, cal-
cium dysregulation, and cardiomyocyte
death, and is considered a potential thera-
peutic target (2). The vast majority of the
>1,000 mitochondrial proteins are encoded
by nuclear genes and are imported. Both
mitochondrial-encoded and nuclear-encoded
proteins undergo folding and/or assembly
into multimolecular complexes within mito-
chondria (3). Under cellular stress conditions,
the mitochondrial protein-folding environ-
ment may be challenged and result in the
production of misfolded, dysfunctional pro-teins. Dysfunction of the mitochondrial respiratory
chain is accompanied by increased generation of
reactive oxygen species (ROS) and oxidative stress,
which in turn compromises protein integrity and
folding—resulting in a vicious cycle of progressively
worsening mitochondrial damage and heart
dysfunction (2).SEE PAGE 1807The mitochondrial unfolded protein response
(UPRmt) is evolutionarily conserved and evoked when
the mitochondrial protein folding environment is
compromised and there is an accumulation of mis-
folded proteins (4). The UPRmt is a mitochondrial-to-
nuclear signal transduction pathway that leads to
increased transcription of numerous mitochondrial
protective genes, notably a repertoire of molecular
chaperones, proteases, and antioxidant enzymes
located primarily in the mitochondrial matrix (5).
These include chaperones (e.g., mitochondrial pre-
sequence translocase-associated motor complex pro-
tein [mtDNAj], heat shock 10kDa protein 1 [Hsp10],
heat shock 60kDa protein 1 [Hsp60]), which facilitate
protein folding or repair misfolded proteins, and
proteases (e.g., ATP-dependent Clp protease proteo-
lytic subunit [ClpP], lon protease homolog,
mitochondrial [LonP1], Htra2), which degrade unre-
pairable and/or truncated proteins for efficient
removal. Activation of the UPRmt serves to restore
mitochondrial protein homeostasis, function, and cell
survival. The UPRmt has been extensively character-
ized in C. elegans (6,7) and demonstrated in yeast (8),
flies (9), and mammalian cells (10), and has beenassociated with potential cytoprotective roles in
diverse models of stress (4,11,12). However, the role of
the UPRmt in the heart is unclear. Here, we identify
the induction of the UPRmt in cardiomyocytes sub-
jected to neurohumoral or mitochondrial stress and in
the hemodynamically overloaded murine and human
heart. We show that pharmacological enhancement of
UPRmt with small-molecule agents ameliorates mito-
chondrial and contractile dysfunction in the over-
loaded murine heart, and in patients with aortic
stenosis, elevated levels of UPRmt indexes correlate
with reduced plasma biomarkers of cardiac damage
and dysfunction. The UPRmt, therefore, has an
important homeostatic role in the pathologically
stressed mammalian heart and may be a potential
therapeutic target in heart failure.
METHODS
Detailed methods appear in the Online Appendix.
Animal procedures were performed in accordance
with the United Kingdom’s legal and institutional
ethical guidelines. Male mice were subjected to
transverse aortic constriction (TAC) or a sham pro-
cedure under isoflurane anesthesia. Oxygen con-
sumption of neonatal rat cardiomyocyte cultures was
quantified on an extracellular flux analyzer (Sea-
horse, Agilent Technologies, Santa Clara, California),
according to the manufacturer’s protocol for mito-
chondrial stress tests. Data were normalized by cell
number. Tissue myocardial oxygen consumption rate
was measured in an Oxytherm (Hansatech, King’s
Lynn, United Kingdom). mRNA levels were quantified
by real-time PCR using SYBR Green and the compar-
ative Ct method, with cytoskeletal b-actin levels used
for normalization. Primer sequences are shown in
Online Table 1. Immunoblotting was performed using
standard methods. Histology of mouse hearts was
performed in paraformaldehyde-fixed samples. Cyclic
AMP-dependent transcription factor ATF-5 (Atf5)
silencing was performed in neonatal cardiomyocytes
using TransFectin-mediated siRNA transfection.
Human studies were performed under institutional
ethical approval and with informed consent. Patients
undergoing valve replacement for severe aortic ste-
nosis were included. Echocardiography was per-
formed pre-operatively, and blood samples were
obtained for biomarkers. Myocardial biopsies were
obtained during surgery and used for mRNA analyses
and histology. Control samples were obtained from
subjects who had died from noncardiovascular causes.
Data are presented as mean  SEM, unless other-
wise stated. Comparisons were made by Student’s
t-test, Mann-Whitney U test, 1-way analysis of
FIGURE 1 Induction of UPRmt Markers Under Various Stress Conditions in Cardiomyocytes and in an In Vivo Model of Chronic Pressure Overload
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FIGURE 2 Enhancement of UPRmt Prevents Stress-Induced Decrease in Mitochondrial Maximum Respiration Rate (Max Resp)
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Iso ¼ isoproterenol; NR ¼ nicotinamide riboside; other abbreviations as in Figure 1.
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FIGURE 3 Enhancement of UPRmt With NR Is Cardioprotective in Mice Subjected to Chronic Pressure Overload
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1799variance (ANOVA), 2-way ANOVA, or repeated mea-
sures ANOVA as appropriate, followed by Bonferroni
post-hoc testing. A p value <0.05 was considered
significant.
RESULTS
UPRmt INDUCTION IN CARDIOMYOCYTES SUBJECTED TO
PATHOLOGICAL STRESSES AND IN THE HEMODYNAMICALLY
OVERLOADED HEART. The induction of the UPRmt
involves the transcription factors Atf5 and CCAT-
enhancer-binding protein homologous protein
(CHOP), which increase the expression of mitochon-
drial chaperones and proteases (10,13). We first tested
the effect of subjecting cultured rat cardiomyocytes
to 4 different pathological stresses: 1) mitochondrial
stress by treatment with the complex I inhibitor
paraquat; 2) neurohumoral stress by treatment with
the b-adrenoreceptor agonist isoproterenol (Iso);
3) mitochondrial stress by treatment with aninhibitor of the mitochondrial chaperone Hsp90,
Gamitrinib-triphenylphosphonium (G-TPP); and
4) mitochondrial protein misfolding stress by the
overexpression of a terminally misfolded mutant
form of mitochondrial ornithine transcarbamylase
(D-OTC) (10). Cardiomyocytes treated with incre-
mental concentrations of paraquat or isoproterenol
showed significant time-dependent increases in the
mRNA levels of Atf5, CHOP, mtDNAj, ClpP, LonP1,
Hsp10, and Hsp60 (Figures 1A to 1D). The increases in
mRNA levels of the mitochondrial chaperones and
proteases were either transient (only at earlier time
points after Iso) or only occurred at later time points
(e.g., after paraquat). Treatment of cardiomyocytes
with G-TPP (10 mmol/l) resulted in significant in-
creases in the mRNA levels of CHOP, LonP1, Hsp60,
and Hsp10 after either 4 or 8 h of treatment
(Figure 1E). Finally, the overexpression of D-OTC also
resulted in significant elevation in the mRNA levels
of Atf5, CHOP, mtDNAj, ClpP, and LonP1 in a similar
FIGURE 4 Effect of Boosting the UPRmt on Myocardial Mitochondrial Respiration in Mice Subjected to TAC or SHAM
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1800range to that reported previously in other systems
(10,13) (Online Figure 1A).
To assess whether UPRmt induction in car-
diomyocytes occurs as a process distinct from the
endoplasmic reticulum unfolded protein response
(ER stress) or cytosolic stress responses, we assessed
the protein levels of KDEL sequence-containing
markers of ER stress (i.e., calreticulin, Grp78, and
Grp79) and mRNA levels of the cytosolic chaperones
Hsp70 and Hsp90 under these stress conditions.
Protein levels of KDEL sequence-containing proteins
were unaltered in cardiomyocytes treated with
isoproterenol, paraquat, or D-OTC overexpression,
whereas stimulation with tunicamycin, which in-
duces ER stress, robustly increased the levels of these
proteins (Online Figure 1). mRNA levels of cytosolic
Hsp70 and Hsp90 were also largely unaltered by the
UPRmt-inducing stress stimuli (Online Figure 1).We next investigated whether the UPRmt is acti-
vated during in vivo pathological cardiac stress
induced by TAC. Analysis of LV tissue 14 days after
TAC showed a significant up-regulation in mRNA
levels of Atf5, ClpP, and LonP1, whereas levels of
CHOP, mtDNAj, and Hsp10/60 remained unaltered
(Figure 1F). TAC resulted in significant cardiac hy-
pertrophy (heart/body weight ratio 6.32  0.34 vs.
4.30  0.11 in SHAM; p < 0.05) and LV contractile
impairment (ejection fraction 26.8  2.1% vs. 62.7 
2.8% in SHAM; p < 0.05).
These data demonstrate for the first time that the
UPRmt is induced in cardiomyocytes subjected to
diverse pathological stresses and in the hemody-
namically overloaded heart in vivo.
AGENTS THAT ENHANCE NADD LEVELS BOOST
UPRmt MARKERS IN CARDIOMYOCYTES AND THE
HEART IN VIVO. Previous studies showed that the
FIGURE 5 UPRmt Markers in Human Myocardium From AS Patients Undergoing Valve Replacement Surgery or Control Subjects
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1801enhancement of cellular NADþ pools, either
directly via supplementation with nicotinamide
riboside (NR) or indirectly via the pharmacological
inhibition of polyADP-ribose polymerase (PARP),
boosts the UPRmt (12,14–16). Consistent with these
data, treatment of cardiomyocytes with NR(1 mmol/l for 18 h) significantly increased the
mRNA levels of Atf5, CHOP, mtDNAj, ClpP, Lonp1,
and Hsp60 (Figure 2A), whereas cytosolic Hsp70
and Hsp90 levels were not increased (Online
Figure 2A). Likewise, the treatment of car-
diomyocytes with the PARP inhibitor olaparib
CENTRAL ILLUSTRATION Mitochondrial Unfolded Protein Response Protects the Heart During Disease Stresses
Smyrnias, I. et al. J Am Coll Cardiol. 2019;73(14):1795–806.
Diverse disease stresses induce the mitochondrial unfolded protein response (UPRmt) in cardiomyocytes, which leads to an increased expression of mitochondrial
chaperones and proteases (e.g., LonP1, ClpP, mtDNAj, Hsp10, Hsp 60). These enhance protein quality control and mitochondrial respiration, thereby enhancing
contractile function and reducing myocyte cell death and fibrosis. Atf5 ¼ cyclic AMP-dependent transcription factor ATF-5; ClpP ¼ ATP-dependent Clp protease
proteolytic subunit; FAD ¼ oxidized flavin adenine dinucleotide; FADH ¼ reduced flavin adenine dinucleotide; H ¼ hydrogen; H2O ¼ water; Hsp10 ¼ Heat shock 10kDa
protein 1; Hsp60 ¼ Heat shock 60kDa protein 1; LonP1 ¼ Lon protease homolog, mitochondrial; mtDNAj ¼mitochondrial pre-sequence translocase-associated motor
complex protein; NAD ¼ oxidized nicotinamide adenine dinucleotide; NADH ¼ reduced nicotinamide adenine dinucleotide; O2 ¼ oxygen.
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crease in the mRNA levels of Atf5, mtDNAj, ClpP,
Lonp1, Hsp10, and Hsp60 while not affecting
Hsp70 and Hsp90 levels (Online Figures 2B and
2C). The in vivo treatment of mice with NR
(750 mg/kg/day intraperitoneally for 3 days) also
significantly upregulated the mRNA levels of Atf5,
CHOP, ClpP, and mtDNAj compared with control
vehicle-treated mice (Online Table 2).PHARMACOLOGICAL ENHANCEMENT OF THE UPRmt
RESCUES MITOCHONDRIAL DYSFUNCTION IN
STRESSED CARDIOMYOCYTES AND IN THE
OVERLOADED HEART IN VIVO. To determine the
functional effect of boosting the UPRmt in stressed
cardiomyocytes, we compared the effects of Iso
(100 mmol/l, 24 h) stimulation on mitochondrial
respiration with and without pre-treatment with NR
or olaparib to enhance the UPRmt. Iso stimulation
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1803resulted in a significant decrease in mitochondrial
maximal respiration, which was markedly improved
when the UPRmt was boosted with NR (Figures 2B and
2C) or olaparib (Online Figures 2C and 2D).
Atf5 is reported to be a key transcriptional inducer
of the mammalian UPRmt (13,17). Indeed, silencing of
Atf5 in cardiomyocytes abolished the Iso-induced
increase in UPRmt markers (Online Figure 3A). To
confirm that the effects of NR are mediated at least in
part through activation of the UPRmt, we silenced Atf5
and then examined the effects of NR on UPRmt
markers. The silencing of Atf5 substantially inhibited
the NR-mediated increase in UPRmt markers (Online
Figure 3B) and abolished the NR-mediated preven-
tion of Iso-induced decrease in mitochondrial respi-
ration (Figures 2D and 2E), strongly supporting the
idea that NR is protective by boosting the UPRmt.
We next tested the effects of boosting the UPRmt
in vivo on cardiac functional responses to TAC-
induced chronic pressure overload. Mice were
treated with NR or control vehicle for 3 days before
subjecting them to TAC. The extent of hypertrophy
induced by TAC was similar in NR- and vehicle-
treated mice (Figure 3A). However, LV function
assessed by the echocardiographic ejection fraction
1 week after TAC was significantly better in
NR-treated compared with vehicle-treated mice
(Figures 3B and 3C). Histological analyses of myocar-
dial tissue from these animals revealed that
NR-treated animals had a significantly lower number
of TUNELþ cardiomyocytes after TAC than vehicle-
treated mice subjected to TAC (Figure 3D). Treat-
ment with NR did not affect the ER stress response
(Figure 3E, Online Figure 4).
We assessed the effect of NR pre-treatment on
mitochondrial respiration in myocardial tissue from
NR- and vehicle-treated mice subjected to TAC or
sham surgery. TAC resulted in a reduced mitochon-
drial complex I- and complex II-dependent oxygen
consumption rate as compared to sham (Figures 4A to
4C). This impairment was significantly improved in
mice pre-treated with NR to induce the UPRmt. No
differences were detected in complex IV-dependent
oxygen consumption rate (Figure 4D). These data
demonstrate that pharmacological boosting of the
UPRmt improves mitochondrial function, car-
diomyocyte survival, and contractile function in ani-
mals subjected to chronic hemodynamic overload.
INDUCTION OF THE UPRmt IN THE HEARTS OF
HUMANS WITH CHRONIC PRESSURE OVERLOAD. To
investigate the relevance of the UPRmt in the patho-
logically stressed human heart, we analyzed
myocardial tissue from patients who underwent valve
replacement surgery for severe aortic stenosis (AS), aclinical model of chronic pressure overload. The
clinical and demographic characteristics of these pa-
tients are shown in Online Table 3. Control myocar-
dial samples were obtained from subjects who had
died from trauma or neurological injury. Gene
expression analyses revealed a significant increase in
the mRNA levels of ClpP, mtDNAj, and CHOP in the
samples from AS subjects compared with control
subjects (Figure 5A). However, we also noted that
there was a wide variation in the mRNA levels of
UPRmt markers among the AS group compared with
control. Notably, approximately 50% of the AS sub-
jects had substantial increases in the expression
levels of these transcripts (Figure 5A).
To elucidate any relationship between the level of
increase in myocardial UPRmt markers and patient
characteristics, we divided the AS patients into 2
groups (subgroups A and B) based on their myocardial
mRNA levels of UPRmt markers being higher or lower
than the upper limit of “normality” (ULN). ULN was
set as 2 SDs above the mean for each transcript in the
control group. Subgroup A comprised AS patients
with mRNA levels of UPRmt markers within the
normal range, and subgroup B comprised those with
mRNA levels of at least 3 UPRmt markers above the
upper limit. Subjects in subgroup B in fact demon-
strated significant elevation of all the UPRmt markers
compared with subjects in subgroup A or control,
indicating a significant activation of UPRmt in this
cohort (Figure 5B).
We compared a range of parameters of clinical AS
severity, hemodynamic state, cardiac structure and
function, myocardial histology, and blood biomarkers
that were assessed pre-operatively between the 2
subgroups. There was no significant difference be-
tween subgroups in age, sex, comorbidities, systemic
blood pressure or AS severity, as assessed by the
mean transvalvular pressure gradient at echocardi-
ography (Online Table 3). Fewer patients had a his-
tory of heart failure in subgroup B than A but this was
not significant. The 2 subgroups had similar maximal
transvalvular pressure gradients, similar LV systolic
contractile function as assessed by ejection fraction,
similar LV end-systolic and -diastolic dimensions,
and a similar extent of hypertrophy as assessed by the
LV mass index or the mean cardiomyocyte area on
myocardial sections (Figure 5, Online Table 3). There
were no significant differences between subgroups in
LV diastolic function as assessed by the Doppler E/A
ratio or mitral E-wave deceleration time. However,
histological analysis of myocardial sections revealed
that subgroup B had significantly lower numbers of
TUNEL-positive cardiomyocytes and a lower degree
of interstitial collagen cross-linking as an index of
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Furthermore, patients in subgroup B had significantly
lower serum levels of both hs-TnT and N-terminal
pro–B-type natriuretic peptide (Figure 5).
Taken together, these data demonstrate that the
UPRmt is induced in the human heart subjected to
chronic pathological pressure overload and that a
high level of activation is associated with reduced
cardiomyocyte cell death, which may consequently
limit pathological fibrosis and overall pathological
cardiac stress.
DISCUSSION
Numerous cellular processes depend upon normal
mitochondrial function, which is required for cellular
metabolism, energy generation, and the regulation of
cell death. The mitochondrial proteome may
be markedly affected by stress conditions that alter
the protein-folding environment (3,4). Well-
characterized, evolutionarily conserved stress re-
sponses are evoked in several cellular compartments
in response to stresses that disrupt protein integrity,
for example, the ER stress response (18), the nucleolar
stress response (19), and the cytosolic heat shock
response (20). These responses typically lead to an
increased expression of proteins that restore organ-
elle homeostasis. The UPRmt was relatively recently
identified and serves an analogous function in the
mitochondria. While it has been comprehensively
characterized in C. elegans (6,7) and identified in
other organisms such as yeast (8) and flies (9), it has
not been extensively studied in mammals. In partic-
ular, the role of the UPRmt in the heart—the organ
with the highest oxygen consumption rate in mam-
mals—is unclear. This study identifies an important
role for the UPRmt in cardiac stress responses, espe-
cially heart failure, where enhancement of the UPRmt
substantially attenuates mitochondrial dysfunction
and contractile failure in the experimental setting
(Central Illustration).
Diverse in vitro stresses, such as neurohumoral
activation and mitochondrial stress, evoked by the
inhibition of complex I by paraquat, inhibition of the
mitochondrial chaperone Hsp90 by G-TPP, or excess
unfolded proteins (resulting from the overexpression
of D-OTC), activated the UPRmt in cultured mamma-
lian cardiomyocytes—as evidenced by the increased
mRNA expression of several mitochondrial chaper-
ones and proteases and the transcription factors Atf5
and/or CHOP (10,13). A similar activation of the cardiac
UPRmt was observed after the imposition of in vivo
hemodynamic overload in the mouse. The level of
increase in mRNA levels of UPRmt markers was in asimilar dynamic range to that reported after genetic
UPRmt induction in C. elegans (21). There were some
variations between stressors in the genes that were
up-regulated among Atf5, CHOP, mtDNAj, ClpP,
LonP1, Hsp10, and Hsp60, which may reflect differ-
ences in the precise regulation of individual genes
(22). Atf5, similarly to ATFS-1, which mediates the
UPRmt in C. elegans (6), is a bZIP transcription factor
that shuttles from the mitochondria to the nucleus
during mitochondrial stress and has been reported as 1
of the key mediators of the mammalian UPRmt (10,13).
Indeed, we show that silencing of Atf5 in car-
diomyocytes blunts the Iso-induced increase in UPRmt
markers. CHOP, on the other hand, is best known to be
associated with the ER stress response (18), but several
studies (including the current study) found a specific
involvement of CHOP in the UPRmt independent of ER
stress (5,10,23). We found that the activation of the
UPRmt occurred distinct from ER stress or the cytosolic
heat shock response as evidenced by the lack of cor-
responding changes in ER stress markers or cytosolic
heat shock proteins (Online Figure 1). We used the
levels of KDEL sequence-containing proteins as an
integrated readout of the ER stress response rather
than dissecting individual limbs of this pathway. It
may be of interest in future studies to look for any
inter-relationship between Atf5 and individual limbs
of the ER stress response, including ER stress-related
transcription factors (e.g., Atf6), and whether these
have any role in the UPRmt. Further studies are also
required to define the precise inter-relationship dur-
ing UPRmt activation between Atf5 and CHOP, which is
normally linked to activation of the ER stress
response.
Activation of the UPRmt has been viewed as a
cytoprotective response that promotes organelle re-
covery (6,24). In our cardiomyocyte studies, we found
that induction of UPRmt markers was typically tran-
sient. We therefore hypothesized that enhancing the
UPRmt might elicit cytoprotective effects. Recent
studies have identified agents that activate the
UPRmt, thereby facilitating characterization of its
functional impact under stress conditions. Notably,
the augmentation of cellular NADþ pools leads to the
induction of the UPRmt, secondary to activation of
NADþ-dependent deacetylases, and was shown to
improve the outcome under conditions of mitochon-
drial stress(12,14–16). Augmentation of NADþ pools
can be achieved via dietary supplementation with
NADþ precursors such as NR, or through the inhibi-
tion of NADþ-consuming enzymes such as PARP. We
confirmed that agents that augment the NADþ pools,
in particular NR, enhance the UPRmt in car-
diomyocytes and that this occurs through the actions
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The detrimental
consequences of chronic hemodynamic overload or neurohu-
moral stress in the heart include mitochondrial dysfunction and
contractile depression. Activation of the UPRmt is able to miti-
gate these effects by restoring mitochondrial homeostasis.
TRANSLATIONAL OUTLOOK: The UPRmt can be activated by
small molecules that increase NADþ levels. Additional studies are
required to determine whether long-term enhancement of the
UPRmt is beneficial in chronic hemodynamic overload.
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1805of Atf5. We found that the augmentation of the UPRmt
led to significant improvement in mitochondrial
dysfunction in stressed cardiomyocytes. Importantly,
these effects were dependent on Atf5, indicating that
they were likely to involve the UPRmt rather than
other NADþ-dependent actions in the cell. To extend
these data to the in vivo setting, we tested the effects
of NR supplementation in mice subjected to TAC. We
found that NR treatment markedly improved mito-
chondrial respiration, cardiomyocyte survival, and
cardiac contractile function. These data provide
proof-of-concept that enhancement of the UPRmt in
the pathologically stressed heart may have thera-
peutic potential.
To extend these findings to the human setting, we
studied myocardial tissue from patients with severe
AS undergoing valve replacement. A comprehensive
molecular and histological analysis of myocardial
tissue, clinical characteristics, and blood biomarkers
revealed a striking relationship between enhanced
activation of the UPRmt and reduced indexes of
ongoing myocardial damage. We found that AS pa-
tients who had an elevation of UPRmt markers had
lower plasma levels of hs-TnT and N-terminal pro–B-
type natriuretic peptide, both strong predictors of
future adverse outcome independent of the resting
LV function (25). They also showed lower levels of
apoptotic cardiomyocytes in myocardial sections and
less abnormal fibrosis than patients with low levels of
UPRmt markers. These findings are consistent with
the postulate from our experimental studies that
increased activation of the UPRmt is beneficial by
preserving mitochondrial function. In the human AS
setting, a chronic improvement in mitochondrial
function may manifest as a lower rate of car-
diomyocyte death, with concomitant lower levels of
fibrosis in the myocardium. Unlike the TAC setting,
AS subjects with elevated UPRmt markers had similar
cardiac function to those with low UPRmt levels,
which may reflect the very slowly-progressive pa-
thology of human AS compared with surgically
induced TAC in mouse models (25). These data iden-
tify for the first time an activation of the UPRmt in the
pressure-overloaded human heart and suggest that
increased activation of the UPRmt may be beneficial.
Activation of the ER stress response has been
demonstrated to be an important pathophysiological
mechanism in many human diseases (18) and small
molecules that modulate this response are under
investigation as potential therapeutic agents (26).
Here, we show that the augmentation of a different
stress response, the UPRmt, may also have beneficial
effects. It should be noted, however, that prolonged
or dysregulated induction of the UPRmt could bedetrimental, for example, contributing to an accu-
mulation of defective mitochondria (27) and neuro-
degenerative phenotypes (28).
STUDY LIMITATIONS. Future studies will need to
investigate the effects of different durations of UPRmt
activation and in different disease settings to better
understand the therapeutic potential and/or toxicity
of such interventions. Another limitation of our study
is the fact that the human data are by necessity
correlative and that the control subjects were not
perfectly matched with the AS patients. However,
there was a very good matching of most clinical
characteristics between AS patients in the two
subgroups.
CONCLUSIONS
In summary, this is the first study to identify activa-
tion of the UPRmt in response to diverse in vitro and
in vivo stresses in the mammalian myocardium. We
also show that pharmacological boosting of the UPRmt
preserves mitochondrial function and cardiomyocyte
viability under pathological stress conditions relevant
to heart failure. Taken together, the results suggest
that the targeting of the UPRmt merits further inves-
tigation as a therapeutic strategy for heart failure.
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